Pompe Disease

This is a specific type of glycogen storage disease. It's caused by a missing enzyme that helps break down glycogen. This leads to glycogen building up in muscles, the heart, liver, and brain. It can cause muscle weakness, heart problems, and sometimes intellectual disability. There are different forms, like infantile, childhood, and adult.

ConditionRare Disease

What people with Pompe Disease report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Pompe Disease?

NameHow it went

About Pompe Disease

What It Is

Pompe disease, also called glycogen storage disease type II or acid maltase deficiency, is an inherited condition in which the body cannot properly break down glycogen, the stored form of sugar that cells keep for energy. Normally an enzyme called acid alpha-glucosidase clears glycogen inside small recycling compartments in cells. When that enzyme is missing or weak, glycogen builds up and damages tissue, mainly muscle. The skeletal muscles that move the body, the heart and the muscles used for breathing are the most affected. Pompe disease is a spectrum. The classic infantile-onset form begins within the first few months of life: babies are unusually floppy and weak, have trouble feeding and breathing, and develop a thickened, enlarged heart. Without treatment, it is usually fatal from heart failure within the first year. A non-classic infantile form appears by about age 1 with delayed motor milestones and progressive weakness; the heart may be enlarged but rarely fails, and weak breathing muscles are the main danger. Late-onset Pompe disease can begin anywhere from childhood to late adulthood. It usually spares the heart and causes slowly worsening weakness in the trunk, hips and thighs, along with weakness of the breathing muscles, including the diaphragm. Over years, that breathing weakness is what most affects health and survival.

Causes & Risk Factors

Pompe disease is caused by changes (variants) in the GAA gene, which carries the instructions for acid alpha-glucosidase. It is inherited in an autosomal recessive pattern: a person develops the disease only when both copies of the gene, one from each parent, carry a variant. Parents who each carry one copy are usually healthy and often have no idea they are carriers until a child is diagnosed. Nothing a person or parent did causes it, and there are no diet or lifestyle triggers. The specific combination of variants influences how early and how severely the disease appears. One variant common in the United States, for example, is generally linked to milder late-onset disease. Pompe disease has been estimated to affect about 1 in 40,000 people in the United States, but newborn screening suggests late-onset forms may be more common than that figure implies. Because it is inherited, brothers and sisters of a person with Pompe disease may also be affected or be carriers, and genetic counseling can explain the chances for other family members and future pregnancies.

How It's Diagnosed

Many babies in the United States are now screened for Pompe disease at birth, since it was added to the national recommended newborn screening panel in 2015, although programs vary by state. A positive screen is not a diagnosis. In one state program, about a third of babies who screened positive were found to have late-onset Pompe disease, and none had the infantile form, so follow-up testing sorts out who has the disease and which form. The central test measures acid alpha-glucosidase activity, often first in a dried blood spot and then in white blood cells, which is more reliable. Genetic testing that finds disease-causing variants in both copies of the GAA gene confirms the diagnosis. Supporting tests can include creatine kinase (CK), a muscle enzyme that leaks into the blood when muscle is damaged, and a urine test for a glycogen breakdown product. In babies, a chest X-ray, an echocardiogram (heart ultrasound) and an electrocardiogram (ECG) look for the thickened heart typical of the infantile form. Infants also have a test of whether their body makes any of the enzyme protein at all, because those who make none are more likely to form antibodies against treatment and may need extra immune therapy. Late-onset disease is often missed for years because hip and trunk weakness can look like other muscle diseases. Clinicians may use muscle strength tests, electromyography (a test of the muscles' electrical activity), muscle MRI or a muscle biopsy, along with breathing tests. One useful breathing test is forced vital capacity, the amount of air a person can blow out after a full breath. A clear drop when the test is repeated lying down instead of sitting suggests a weak diaphragm.

Treatment Options

There is no cure, but enzyme replacement therapy (ERT) has changed the outlook. ERT is a lab-made version of the missing enzyme, given as an intravenous (IV) infusion every two weeks, usually for life. Alglucosidase alfa (Lumizyme) is approved for all forms of Pompe disease. Avalglucosidase alfa (Nexviazyme) is approved for late-onset disease from age 1. Cipaglucosidase alfa (Pombiliti), taken together with miglustat capsules (Opfolda) that help stabilize the enzyme, is approved for adults with late-onset disease who weigh at least 40 kg and are not improving on their current ERT. For the infantile form, treatment should start as early as possible, ideally within the first weeks of life. ERT shrinks the thickened heart, improves movement and breathing, and greatly extends survival. In one series of babies treated within their first month, nearly all were later walking, eating by mouth and breathing without a ventilator. Some infants form antibodies that blunt the enzyme's effect, so doctors check antibody levels and, for babies at high risk, add medicines that calm this immune response. In late-onset disease, experts generally recommend starting ERT once there is muscle weakness or breathing-muscle involvement. On average, after about a year people walk modestly farther in a 6-minute walk test than with placebo, and treatment tends to stabilize function for one to three years. Slow decline often resumes afterward, and there is no clear evidence that one ERT product works better than another over the long term. Switching products may be considered if function keeps worsening. The main trade-off of every ERT is infusion and allergic reactions, which can rarely be severe (anaphylaxis). Infusions start in a clinic with emergency treatment on hand, and some people later move to home infusions. Cipaglucosidase alfa with miglustat may harm a developing pregnancy, so women who could become pregnant need effective contraception while taking it and for a period afterward. Supportive care matters as much as the enzyme. Breathing support ranges from airway clearance and a cough-assist device to a ventilator used at night or longer, often through a mask. Physical therapy helps preserve strength and mobility, and dietitians and speech therapists help with nutrition and swallowing. Babies with heart strain may need heart medicines alongside ERT. Gene therapy and other new approaches are being studied but remain research.

What to Expect

Care is usually coordinated by a specialist center with a team that may include metabolic and neuromuscular specialists, lung and heart doctors, physical therapists and dietitians. ERT means an infusion visit, or a home infusion, every two weeks. For late-onset disease, check-ups typically happen every 6 to 12 months once things are stable, with yearly breathing tests and regular strength and walking assessments. Treated infants are seen more often, about every 3 to 6 months. The course differs by form. Infants treated early now often grow into school age and beyond, but they need lifelong monitoring of antibodies, muscle strength and especially heart rhythm, because problems with the heart's electrical system can appear years later even when the heart muscle has improved. Current enzyme treatments do not reach the brain well, and some long-term survivors develop learning or neurological issues that are still being studied. In late-onset disease, weakness usually progresses slowly over years and decades. Everyday movements that depend on the hip and trunk muscles, such as getting up or walking longer distances, may gradually become harder, and some people eventually use a mobility aid or wheelchair. Breathing-muscle weakness often shows first during sleep, so many people use breathing support at night. Swallowing problems, constipation, falls and thinning bones can also occur. Respiratory failure and chest infections are the leading disease-related causes of death, which is why breathing is monitored closely and treated early. Babies identified through newborn screening with late-onset results are often watched rather than treated at first, since many stay well for a long time; families can find this uncertainty hard, and it is worth discussing openly with the care team.

When to Seek Help

Ask for an evaluation if you have slowly increasing weakness in your hips, thighs or trunk, an unexplained high CK level, or a family member with Pompe disease, and arrange genetic counseling if you are planning a pregnancy and Pompe disease runs in your family. A baby who is unusually floppy, feeds poorly or struggles to breathe should be seen by a doctor promptly. If you already have Pompe disease, contact your care team right away about headaches on waking, new daytime sleepiness or fatigue, more frequent falls, a noticeable loss of strength or everyday abilities, a chest infection, or new trouble swallowing. These can signal that breathing muscles are weakening or that treatment needs review. Call 911 for severe difficulty breathing, or for signs of a serious allergic reaction during or after an infusion, such as swelling of the face or throat, wheezing or feeling faint.

Questions to Ask Your Doctor

  1. 1.Which form of Pompe disease do I or my child have, and what does that mean for how quickly it may change?
  2. 2.Is it the right time to start enzyme replacement therapy, and how will we judge whether it is working?
  3. 3.How should my breathing be checked, and when would breathing support at night help?
  4. 4.What should our team watch for with the heart, swallowing and bones over the next few years?
  5. 5.Should other family members be tested, and what are the options for future pregnancies?

Last reviewed • Oct 2026

Educational content, not medical advice.